CLEC12A and acute myeloid leukemia: Analysis of samples obtained during diagnosis and relapse, even from the peripheral blood of patients who are treated with G-CSF, revealed that AML blasts consistently exhibit CLL-1 expression with no variation in antigen density, establishing CLL-1 as a stable marker for monitoring disease progression and detecting MRD; however, it can be inferred that neither chemotherapy nor G-CSF treatment upregulates CLL-1 expression in LSCs [11, 27, 31, 33, 34].